カーボンイオンとフォトン放射線で治療された再発性鼻がんに対するPARP阻害剤のオートファギー依存的敏感化効果
Ziyu Le1,2,3, Haojiong Zhang1,2,3, Li Chen1,2,3
1Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai 201315, China.
Acta biochimica et biophysica Sinica
|September 2, 2025
まとめ
オラパリブは,再発性鼻がん (NPC) の放射線治療に対する癌細胞の感受性を高めます. オートファギーはこの放射線感受性効果において重要な役割を果たし,潜在的な新しい治療戦略を提供します.
科学分野:
- 腫瘍学
- 放射線腫瘍学
- 分子生物学
背景:
- 再発性鼻がん (NPC) は,腫瘍の放射線抵抗性および治療の毒性により重大な課題を提示する.
- 再発性NPCの患者にとって,再照射は重要だが難しい選択肢である.
研究 の 目的:
- 繰り返し発生するNPC細胞を光子と炭素イオン (Cイオン) 放射線に敏感にするためのポリアダプリボゼポリメラーゼ (PARP) 阻害剤オラパリブの有効性を評価する.
- オラパリブと電離放射線による結合細胞死促進のメカニズムを解明する.
主な方法:
- 再発性NPC細胞と光子耐性モデル (HK-RR) に対するオラパリブの放射線感受性作用を調査した.
- 放射線,特にCイオン被曝によって誘発された遺伝子発現の変化を,同類再結合 (HR) 能力に関連して分析した.
- アポプトーシス,ネクロシス,フェロプトーシス,老化,自殺細胞死 (ACD) を含む複数の細胞死経路の評価.
- オラパリブの放射線感受性作用に対する自己消化の薬理学的および遺伝的抑制の影響を調査した.
主要な成果:
- オラパリブは,再発性NPC細胞とHK-RRモデルにおいて,X線とCイオン放射線に対する有意な放射線感受性効果を示した.
- Cイオン放射線は,HRに適したNPC細胞にHR欠乏性遺伝子シグネチャを誘導し,PARP阻害に対する感受性の増加を示唆した.
- オラパリブと放射線治療を併用すると,様々な細胞死が誘発され,ACDは主要な経路であった.
- 薬理学的または遺伝的手段による自己消化抑制は,オラパリブの放射線感受性の効果を大幅に低下させた.
結論:
- オラパリブは,再発したNPC細胞をX線とCイオン放射線の両方に効果的に敏感にします.
- オラパリブの放射線感受性作用の重要な媒介体である.
- この研究は,自己死性の調節が重要な要因として,再発性NPCに対するPARP抑制と放射線を組み合わせた有望な治療戦略を強調しています.
関連する概念動画
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Long-patch Base Excision Repair
7.2K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
7.2K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
259


